Braxia Scientific enters the U.S. Telemedicine sector with the acquisition of KetaMD

Braxia Scientific CEO Dr Roger McIntyre and Warren Gumple, Co-founder of KetaMD joined Steve Darling from Proactive to share news the company has acquired KetaMD which is a U.S. based telemedicine company treating metal health challenges with access to technology-facilitated ketamine-based treatments.

McIntyre telling Proactive KetaMD’s uses technology to provide patient access to at-home ketamine treatments for people suffering from depression and related mental health conditions.

Gumple telling Proactive more about their history and how the process works including the medically supervised experience led by registered nurses with mental health expertise and psychiatrists.

© 2022 Stockmark.it The Latest StockMarket News and Interviews